Clinical Trial Update: CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CC-486 (oral azacitidine) in combination with nivolumab for patients with recurrent or refractory classical Hodgkin lymphoma after PD-1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• CC-486 (azacitidine)
• nivolumab (nivolumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING